Inclusion criteria for pharmacodynamic and clinical trials in chronic idiopathic constipation: pitfalls in using Rome III for functional constipation
- 9 May 2011
- journal article
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 4 (3), 159-163
- https://doi.org/10.1177/1756283x11401773
Abstract
No abstract availableThis publication has 23 references indexed in Scilit:
- Digital Rectal Examination Is a Useful Tool for Identifying Patients With DyssynergiaClinical Gastroenterology and Hepatology, 2010
- Scintigraphic Biomarkers for Colonic DysmotilityClinical Pharmacology & Therapeutics, 2010
- Relationships between pelvic floor symptoms and function in irritable bowel syndromeNeurogastroenterology & Motility, 2010
- Effects of Velusetrag (TD‐5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipationNeurogastroenterology & Motility, 2009
- Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation – a 12‐week, randomized, double‐blind, placebo‐controlled studyAlimentary Pharmacology & Therapeutics, 2008
- Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxativesGut, 2008
- M1806 Complaints Suggestive of Irritable Bowel Syndrome Are Common in Patients with Puborectalis Dyssynergia: An Under-Recognized Overlap SyndromeGastroenterology, 2008
- Functional Bowel DisordersGastroenterology, 2006
- Childhood Functional Gastrointestinal Disorders: Child/AdolescentGastroenterology, 2006
- Biofeedback Is Superior to Laxatives for Normal Transit Constipation Due to Pelvic Floor DyssynergiaGastroenterology, 2006